Timing clarification: ResMed reports today, Thursday, August 6, 2026, after the NYSE close—not tomorrow. The earnings call begins at 4:30 p.m. ET / 1:30 p.m. PT. (investor.resmed.com)
ResMed enters the report with strong operating momentum but a much more complicated fiscal 2027 bridge. The June-quarter numbers matter, especially device growth and gross margin, but the stock’s reaction will probably be driven primarily by:
The stock closed August 5 at $224.07, down about 20% from a year earlier, although it has recovered roughly 23% from its June low. That leaves expectations and valuation less demanding than they were entering prior reports.
Published consensus figures differ modestly by provider:
| Metric | Street expectation | Q4 FY2025 actual | Implied growth |
|---|---|---|---|
| Revenue | Approximately $1.46–$1.47B | $1.348B | Roughly 8%–9% |
| Non-GAAP EPS | Approximately $2.88–$2.92 | $2.55 | Roughly 13%–15% |
Benzinga lists consensus at $1.46 billion and $2.88, while another published aggregation has $1.47 billion and $2.92. (benzinga.com)
At those estimates, full-year fiscal 2026 results would be approximately:
The company most recently reiterated the following fiscal 2026 targets:
Fiscal Q3 was led by masks and accessories:
Overall Q3 revenue was $1.43 billion, up 11% reported and 8% in constant currency, while non-GAAP EPS increased 21% to $2.86. (investor.resmed.com)
Masks are strategically important because they provide recurring revenue and tend to carry favorable economics. Another quarter of low-double-digit mask growth would support management’s claim that new fabric-based AirTouch masks are driving adoption and share gains rather than merely shifting sales between ResMed products.
The questions to ask are:
A result driven mainly by masks would likely be viewed more favorably than one reliant on acquisition revenue or currency.
Device growth was a solid 6% in Q3, but this is where investors will look for evidence of:
Mid-single-digit device growth is probably sufficient. A slowdown toward low single digits, especially in the Americas, would revive concerns that ResMed’s elevated market share is normalizing faster than expected.
Conversely, another 5%–7% result would suggest that demand generation, replacement programs and broader sleep-apnea awareness are offsetting increased competition.
Non-GAAP gross margin reached 62.8% in Q3, up 290 basis points year over year and 50 basis points sequentially. The gains came from lower component costs plus manufacturing and logistics efficiencies. (investor.resmed.com)
That improvement has driven earnings growth well above revenue growth, but the comparisons are becoming harder. Management has acknowledged emerging component inflation, fuel costs and broader geopolitical uncertainty. Morgan Stanley’s June downgrade specifically cited limits to near-term margin expansion and more modest earnings growth expectations. (finance.yahoo.com)
For Q4, the important threshold is likely around 62.5%–63% non-GAAP gross margin:
More important than Q4 itself will be whether management still expects annual gross-margin improvement through 2030 and what fiscal 2027 guidance assumes.
ResMed agreed to sell MatrixCare for $490 million in cash, with closing expected during fiscal Q1 2027. Management intends to use proceeds partly for an accelerated share-repurchase program. MatrixCare contributed approximately:
Transition-service payments are expected largely to offset stranded costs during the first year after closing. Brightree and MEDIFOX DAN are not included in the sale. (investor.resmed.com)
The divestiture should improve ResMed’s strategic focus and underlying growth mix, but it creates several moving parts:
Investors should focus on organic continuing-operations growth, not simply reported consolidated growth.
ResMed completed its $340 million acquisition of Noctrix, adding the Nidra therapy for restless legs syndrome. For fiscal 2027, management expects Noctrix to contribute approximately:
Noctrix could become strategically meaningful, but fiscal 2027 is an investment year. A credible path toward reimbursement expansion, higher sales and eventual accretion would help investors look beyond the initial dilution.
The bear case holds that weight-loss drugs will reduce the incidence and severity of obesity-related obstructive sleep apnea, shrinking demand for CPAP devices.
ResMed’s counterargument is that sleep apnea has causes beyond weight and that GLP-1 treatment is increasing screening and diagnosis. Management says its claims and resupply analyses show that patients prescribed both PAP and GLP-1 therapy are more likely to begin PAP treatment and remain active in mask resupply.
The report should be judged on operational evidence rather than another broad defense of the thesis:
Continued 5%–7% device growth and double-digit mask growth would be more persuasive than additional retrospective datasets alone.
At the end of March, ResMed had approximately $1.7 billion of cash, $664 million of gross debt and nearly $1.0 billion of net cash. Q3 free cash flow was approximately $520 million, and the company returned $262 million through dividends and repurchases.
Management subsequently indicated that fiscal Q4 repurchases had exceeded $200 million and that fiscal 2027 repurchases could exceed $800 million. The MatrixCare proceeds create additional capacity.
Investors should listen for:
At roughly $224, repurchases are more accretive than they would have been when the shares traded near $280 a year ago.
Management has said recent competitive launches have not materially affected market share, but investors will want quantitative reassurance. Philips’ return and Fisher & Paykel’s product development remain the most obvious long-term risks.
Premium fabric masks may improve comfort and adherence, but higher acquisition costs can pressure provider economics under fixed reimbursement. Any indication that customers are limiting adoption because of profitability would weaken the product-mix thesis.
Investors should also monitor payer utilization-management models that could alter the route through which U.S. patients obtain equipment and resupplies.
ResMed’s supply chain has become materially more efficient, but component inflation, tariffs and fuel or freight costs could limit further gross-margin expansion. The risk is less an immediate margin collapse than a transition from large annual gains to only modest improvement.
Aaron Bloomer became CFO following Brett Sandercock’s retirement. This will be Bloomer’s first fiscal year-end call as CFO, making the quality and clarity of the fiscal 2027 outlook especially important.
This would reinforce the view that GLP-1 concerns and competitive fears are not appearing in actual demand.
An in-line quarter could still produce a constructive reaction if the fiscal 2027 outlook is credible and cleanly explained.
The most damaging combination would be slower core-device demand plus evidence that the gross-margin expansion cycle has peaked.
The fiscal Q4 hurdle looks manageable: approximately 8%–9% revenue growth and low-to-mid-teens adjusted EPS growth. ResMed’s recent execution supports at least an in-line result, particularly given strong mask demand and continued supply-chain productivity.
However, the quarter is secondary to the fiscal 2027 outlook. Investors need a bridge that separates:
The most bullish outcome is not simply an EPS beat. It is evidence that ResMed can sustain mid-single-digit device growth, double-digit recurring mask growth and incremental margin improvement while simplifying its portfolio. If management can establish that framework, the stock’s compressed valuation leaves room for a favorable re-rating. If fiscal 2027 guidance instead points to slowing organic demand and little further operating leverage, a routine Q4 beat may not be enough.